Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Policy / Regulatory

Kobayashi Pharmaceutical Recalls Red Yeast Rice Pills in China Amid Health Concerns

Fineline Cube Mar 26, 2024

Japan-based Kobayashi Pharmaceutical has reportedly initiated a product recall in the Chinese market for its...

Company Policy / Regulatory

Surprise Resignation: Congressman Gallagher Steps Down as Biosecure Act Faces Uncertainty

Fineline Cube Mar 26, 2024

U.S. Congressman Mike Gallagher, the key proponent behind the recently introduced Biosecure Act aimed at...

Company Deals

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Deal Amid Biotech Pressures

Fineline Cube Mar 26, 2024

U.S.-based biotech Nuvation Bio Inc. (NYSE: NUVB) has announced a definitive agreement to acquire China-based...

Company Drug

FDA Grants Full Approval to AbbVie’s Elahere for Advanced Ovarian Cancer Treatment

Fineline Cube Mar 26, 2024

This week, the U.S. Food and Drug Administration (FDA) granted full approval to AbbVie’s (NYSE:...

Company Deals Hospital

Fosun Health and Adventist Medical Center Partner to Enhance GBA Medical Services

Fineline Cube Mar 26, 2024

China-based Fosun Health Consumption Industry Group has entered into a strategic partnership with Hong Kong’s...

Company Deals Drug

Biocytogen and ABL Bio Forge Partnership to Advance Bispecific ADC Development

Fineline Cube Mar 26, 2024

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with South...

Company Deals

HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups

Fineline Cube Mar 26, 2024

China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science...

Company Drug

CanSino Biologics Launches Phase III Study for Menhycia Vaccine in Indonesia

Fineline Cube Mar 26, 2024

China-based CanSino Biologics (HKG: 6185) has announced the launch of a Phase III clinical study...

Company Deals

Novo Nordisk Acquires Cardior for €1.025 Billion to Strengthen Cardiovascular Portfolio

Fineline Cube Mar 26, 2024

Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a...

Company

Kelun-Biotech Reports Robust 91.6% Revenue Growth Amid Strategic Licensing Efforts

Fineline Cube Mar 26, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) reported its 2023 financial results, revealing revenues of...

Company Drug

Guangdong Zhongsheng Reports Positive Phase I Results for Innovative Weight Loss Drug RAY1225

Fineline Cube Mar 26, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based biopharmaceutical company, has announced promising top-line...

Company Medical Device

Zylox-Tonbridge Secures NMPA Approval for Advanced Flow Diverter Targeting Intracranial Aneurysms

Fineline Cube Mar 26, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Deals

Novo Nordisk Expands Benzalkonium Chloride Distribution with Actylis Across Europe

Fineline Cube Mar 26, 2024

Denmark’s Novo Nordisk (CPH: NOVO-B), through its Pharmatech division, announced a partnership this week with...

Company

WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business

Fineline Cube Mar 26, 2024

WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Jiangsu Hengrui’s Generic Version of Tepadina Approved for Transplantation Conditioning in China

Fineline Cube Mar 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC

Fineline Cube Mar 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...

Company

Sandoz Expands Antibiotics Production with New Austrian Factory

Fineline Cube Mar 25, 2024

Sandoz (OTCMKTS: SDZNY), a Swiss pharmaceutical company, has announced the opening of a new antibiotics...

Company Drug

Shanghai Institute’s Biosimilar Rituximab Approved by NMPA for Lymphoma Treatments

Fineline Cube Mar 25, 2024

Shanghai Institute of Biological Products Co., Ltd has announced that its biosimilar version of Roche/Genentech’s...

Company Drug

EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision

Fineline Cube Mar 25, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company

Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market

Fineline Cube Mar 25, 2024

Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of...

Posts pagination

1 … 385 386 387 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.